|Project Title||Principal Investigator||Institution|
|Abnormal vestibulo-ocular reflexes in autism: A potential endophenotype||White, Keith||University of Florida|
|ACE Center: Assessment Core||Klin, Ami||Yale University|
|ACE Center: Clinical Phenotype: Recruitment and Assessment Core||Pierce, Karen||University of California, San Diego|
|ACE Center: Gaze perception abnormalities in infants with ASD||Chawarska, Katarzyna||Yale University|
|ACE Center: Integrated Biostatistical and Bioinformatic Analysis Core (IBBAC)||Schork, Nicholas||University of California, San Diego|
|ACE Center: Linguistic and social responses to speech in infants at risk for autism||Kuhl, Patricia||University of Washington|
|ACE Center: MRI studies of early brain development in autism||Courchesne, Eric||University of California, San Diego|
|ACE Network: A longitudinal MRI study of infants at risk for autism||Piven, Joseph||University of North Carolina at Chapel Hill|
|A longitudinal 3-D MRSI study of infants at high risk for autism||Dager, Stephen||University of Washington|
|Are autism spectrum disorders associated with leaky-gut at an early critical period in development?||Dobkins, Karen; Schmid-Schoenbein, Geert||University of California, San Diego|
|Biomarkers for autism and for gastrointestinal and sleep problems in autism||Anderson, George||Yale University|
|Brain-behavior growth charts of altered social engagement in ASD infants||Klin, Ami||Yale University|
|Defining high and low risk expression of emotion in infants at risk for autism||Hannigen, Sarah||University of Pittsburgh|
|Developmental characteristics of MRI diffusion tensor pathway changes in autism||Conturo, Thomas||Washington University|
|Development of neural pathways in infants at risk for autism spectrum disorders||Dobkins, Karen||University of California, San Diego|
|Development of neural pathways in infants at risk for autism spectrum disorders (supplement)||Dobkins, Karen||University of California, San Diego|
|Early identification of autism: A prospective study||Iverson, Jana||University of Pittsburgh|
|Early social and emotional development in toddlers at genetic risk for autism||Campbell, Susan||University of Pittsburgh|
|Electrophysiological, metabolic and behavioral markers of infants at risk||Nelson, Charles||Children's Hospital Boston|
|Family/Genetic study of autism||Smith, Christopher||Southwestern Autism Research & Resource Center (SARRC)|
|Identification of lipid biomarkers for autism||Kang, Jing||Massachusetts General Hospital|
|Identifying gastrointestinal (GI) conditions in children with autism spectrum disorders (ASD)||Winter, Harland||Harvard Medical School|
|Infants at risk of autism: A longitudinal study||Ozonoff, Sally||University of California, Davis|
|Metabolic biomarkers of autism: Predictive potential and genetic susceptibility||James, Sandra||Arkansas Children's Hospital Research Institute|
|Misregulation of BDNF in autism spectrum disorders||Hempstead, Barbara||Weill Cornell Medical College|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.
IACC Recommended Budget: $33,300,000 over 5 years
|1.L.A. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.
Remaining Gaps, Needs, and Opportunities: Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.